Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
BR115
- Development stage
- Phase 1
- Lead developer
- BioRay Pharmaceutical
- Modality
- Trispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, T-cell Engagers → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
BR115 is a trispecific T-cell engager antibody designed for the treatment of advanced malignant solid neoplasms. It targets and binds to two separate HER2 epitopes on HER2-expressing tumor cells and CD3 on T cells, facilitating cross-linkage that may trigger a potent cytotoxic T-lymphocyte (CTL) response against HER2-expressing tumor cells. Some sources also indicate potential targeting of CD19 and CD20 in addition to HER2 and CD3. The drug is administered intravenously and is currently in Phase 1 clinical trials for solid tumors. It was initially developed by Chengdu Chimagen Biosciences and is being further developed by BioRay Biopharmaceutical.
- Other names
- anti-HER2/CD3 tri-specific antibody BR115
02
Targets
ERBB2 (Erb-b2 receptor tyrosine kinase 2)CD3 (T-cell surface glycoprotein CD3)CD20 (B-lymphocyte antigen CD20)CD19 (B lymphocyte antigen CD19)
Beyond the preview
Go deeper on BR115.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on BR115.